https://www.selleckchem.com/pr....oducts/4-aminobutyri
BACKGROUND Vancomycin has been used in clinical practice for over 50 years; however, validated, pharmacokinetic (PK) data relating clinical outcomes to different dosing regimens in neonates are lacking. Coagulase negative staphylococci (CoNS) are the most commonly isolated organisms in neonatal, late-onset sepsis (LOS). Optimised use to maximise efficacy while minimising toxicity and resistance selection is imperative to ensure vancomycin's continued efficacy. METHODS NeoVanc is a European, open-label, Phase IIb, randomised,
Like
Comment
Share
